<DOC>
	<DOCNO>NCT00488709</DOCNO>
	<brief_summary>The study design drug use frequently treatment AML , new combination less toxic , effective AML multidrug resistant . Justification : - The AML patient primary resistance relapse first 12 month CR , second line chemotherapy low response rate . - These patient AML primary resistance relapse , reach remission rescue treatment , interval free survival global survival short - Probably resistance treatment relation different form expression MDR . - Complete remission consider valid evaluation , every patient obtain CR consider eligible possible curative treatment : Ara-C administration high dos TPH treatment</brief_summary>
	<brief_title>Fludarabine , Cytarabine , Topotecan Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>It protocol open , multicentric , led end increase ) rate complete response , b ) duration response , c ) free survival disease ) global survival . The included subject patient primary secondary AML achieve CR standard treatment anthracycline derivative associate Ara-C relapse first 12 month achieve RC . Also patient AML , reason , could receive standard treatment anthracycline Ara-C , include Cycle induction . The patient treat FLAT accord follow scheme : - FLUDARABINE , 30 mg/m2 i.v . ( In 1 hour ) 1st 4 . - CITARABINE , 2 g/m2 i.v . ( In 4 hour ) , four hour finish fludarabine , 1st 4 . - TOPOTECAN , 1,5 mg/m2 i.v . ( In 4 hour ) , four hour finish cytarabine , 1st 4 . When patient start recover hematological count , provide blast peripheral blood ( SP ) , become medullar revision ( MO ) : - If MO present severe hypocellularity without blast , therapeutic measurement take repeat revision weekly MDR 's study CR blast appearance . - If MO persist blast ( &gt; 5 % ) diminish less 50 % initial number , induction continue FLAT 's second shift . - If MO persist 50 % blast initial number , patient go protocol treat agreement criterion center . The patient manage enter CR receive cycle consolidation soon possible always within 2 month day receive first FLAT 's dose . The cycle consolidation consist another FLAT 's scheme dos .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Subjects 18 year age major , diagnosis primary secondary AML , confirm cytologically , fulfill one follow condition : Do reach CR conventional treatment . Relapse first 12 month CR . During remission , patient treat transplant . The relapse define presence blast peripheric blood presence &gt; 5 % blast MO . Not participation clinical trial . 2 . ECOG &lt; = 2 3 . Considered suitable patient intensive chemotherapy 4 . Informed consent 1 . Pelvic spinal radiotherapy 4 week incorporation protocol . 2 . Acute promyelocytic leukaemia 3 . First line chemotherapy AML contain fludarabine topotecan . 4 . Active chronic hepatitis hepatic cirrhosis . 5 . Positivity know virus human immunodeficiency ( HIV ) 6 . Pregnant breastfeeding patient . 7 . Patients deterioration function hepatic renal , define follow value base laboratory : AST ALT &gt; 2,5 time top limit normality center ( LSNC ) Alkaline phosphatase &gt; 2,5 time LSNC Total bilirubin value &gt; 2 time LSNC Creatinine value &gt; 2 time LSNC suitable hydration 8 . Precedents intervention major surgery 2 week incorporation protocol . 9 . Patients disease serious control ( example control diabetes , infection , hypertension , etc. ) . 10 . Patients receive cytotoxic drug ( except hydroxyurea reduce leucocytosis ) treatment current relapse resistance , 4 week protocol . 11 . Patients hypersensitivity know someone drug protocol . 12 . Patients treat previously growth factor purpose sensibilization . 13 . Patients psychological , intellectual sensitive dysfunction reduce capacity comprehension fulfillment protocol . 14 . Patients treat FLAT .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Multi Drug Resistance</keyword>
</DOC>